Category Archives: Massachusetts Stem Cells

Intellia Therapeutics (NASDAQ:NTLA Get Rating) and VolitionRx (NYSE:VNRX Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

This is a summary of recent ratings and recommmendations for Intellia Therapeutics and VolitionRx, as reported by MarketBeat.

Intellia Therapeutics currently has a consensus target price of $128.00, suggesting a potential upside of 88.96%. Given Intellia Therapeutics higher probable upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than VolitionRx.

This table compares Intellia Therapeutics and VolitionRxs net margins, return on equity and return on assets.

This table compares Intellia Therapeutics and VolitionRxs gross revenue, earnings per share (EPS) and valuation.

VolitionRx has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.

Intellia Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Intellia Therapeutics beats VolitionRx on 8 of the 13 factors compared between the two stocks.

(Get Rating)

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

(Get Rating)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post here:
Head to Head Analysis: VolitionRx (NYSE:VNRX) vs. Intellia Therapeutics (NASDAQ:NTLA) - Defense World

Alex Christopher, 34, who lives in Brinscall, donated his cells over three years ago when he signed on the donor register in a bid to help his friend and colleague Peter McCleave, 40.

He might not have been a match for his friend, but for Patrick Languzzi who lives in Boston, Massachusetts, in America, Alex proved to be a life-saver.

Patrick had been diagnosed with a rare blood cancer and given a three per cent chance of survival.

In January this year the pair met for the first time over a Zoom call where Alex told Patrick of his friend's plight and both gents made a pact to help gain more donors.

Peter, who was diagnosed with myeloma in 2017 and told that he has seven years to find a match for a lifesaving stem cell donation, set up a campaign to collect an initial 10,000 donors and is now targeting 100,000.

Why did Alex sign up?

Alex, who works for the investment arm of Natwest, said: "I signed up on a whim to help my friend Peter but sadly I was not a match.

"Peter is still looking for his match as a lot of people think 'it won't be me' and I held the same mindset until it was.

"You have the power to change an individual's life and not just theirs but also their family and friends.

"I have seen first hand the effect it has had on Patrick's friends.

"I was a 100 per cent match for Patrick and someone that maybe hasn't registered could be the same for Peter."

Although it was sad circumstances that brought him Alex on his journey, the father of one said all three men have formed a group chat and speak all the time.

"We attended the DKMS London Gala in May together and raised 1.5 million, said the former Lancaster Royal Grammar School pupil from Morecambe.

"It was very strange with models and influencers and some pledging 10,000."

What does Alex say to people afraid to sign up?

Alex explains he did not have to undergo any painful or invasive procedures - his stem cells were extracted from blood taken intravenously at a private clinic in London, then the blood was returned to him, equating to three hours and 45 minutes.

"I would say to people just do it as the more people who sign up the better the odds are for the people waiting on their matches.

"It is so straight forward and easy."

Speaking highly of Peter, Alex added that even though he has been waiting a long time for his genetic twin to come along as he has a very specific DNA composite.

"For him to get a match would be a nice end, but he wouldn't stop going as he would want to continue helping others.

How can you sign up to be a stem donor?

DKMS is a blood cancer charity based in London that registers blood stem donors. Every 20 minutes someone in the UK is diagnosed with a blood cancer and for many a blood stem donation is their best chance of survival.

Read the original:
Man who saved life as stem cell donor urges others to help his friend find a match after five-year search - Lancashire Evening Post

The increasing focus on discovering alternatives to animal testing, the expanding focus on customized therapy, the rising incidence of chronic diseases, and the availability of research funding are all driving 3D cell culture market forward. However, over the projection period, the absence of infrastructure for 3D cell-based research and the high cost of cell biology research are projected to limit the markets growth.Testing on animals has been the most common technique in various experimental trial studies in biomedical research because they resemble humans in terms of genetics, anatomy, and physiology. Mice genome structure Is 80% similar to humans, which makes them excellent replicas for various research works. On the other hand, the use of animals in scientific research is associated with several ethical concerns, which led to the formation of the code of 3Rs- Reduction, Replacement, and Refinement, to address the moral concerns related to animal wellbeing and limit the use of animals in scientific research.

As of 2018, this initiative led to a 50% decrease in the use of animals as compared to the statistics from 1985. Additionally, the practice of animal breeding housing for scientific purposes is also associated with high costs and needs skilled labor. Furthermore, it has been confirmed that animal cell cultures are unable to precisely mimic the natural (in vivo) microenvironment as the cells cultured in monolayers are both morphologically and physiochemical different from their in vivo counterparts. These concerns have demanded a transition from animal testing to the use of 3D cell culture models. Over time the advancement in biotechnology and materials science has enabled the development of a variety of 3D cell culture systems to determine the research across different areas, including cancer research, drug discovery, tissue engineering, and others.

Click Here to Download and Understand Latest Key Trends On Global 3D Cell Culture Market

https://skyquestt.com/sample-request/3d-cell-culture-market

More than 140 companies offer 3D cell culture systems at present in a variety of formats, which includes scaffold-based products, scaffold-free products, and 3D bioreactors. These systems have been confirmed to be capable of more precisely simulating the natural tissue microenvironment, offering increased cell to cell and cell to ECM connections, more precise evaluation of drug toxicity and cellular responses, and culturing multiple cell types together. Furthermore, there are definite complex 3D cell culture models that can even replace animal models demonstrating reproducible results and thus, serving as better in-vivo models across multiple applications. Given the various benefits of such systems, the field has gathered the attention of various VC firms and strategic investors that have been providing monetary support to drive research efforts focused on exploring different formats of 3D cell culture systems, including organoids and organ on chips across multiple use case. Additionally, there has been an increase in the scientific works on 3D cell culture systems and partnerships for 3D bioreactors and cell culture products. Given the current innovation in this field and the pattern shift from 2D cell culture systems and animal testing to 3D cell culture models, the market is likely to witness significant growth in the predicted future.

The North American region accounted for the highest revenue share of over 43% and led the global 3D cell culture market in 2020. The region will hold its leading position throughout the forecast period. The availability of private and government funding for the innovation of advanced 3D cell culture models accounts for this growth in the region. High healthcare spending and the presence of numerous universities and research organizations investigating various stem cell-based methods push the growth in the sector. Researchers from Mayo Clinic and Terasaki Institute in the US developed visible hydrogels that can be used for the monitoring and control of hemorrhage, in December 2020. Asia Pacific is likely to grow at the fastest CAGR in the global 3D cell culture market and is likely to continue the same trend during the forecast period. This is attainable due to growing investments by several companies and rising healthcare spending in developing economies like China and India in the region. Also, government support & planned initiatives are expected to support the growth of the market in near future.Read the market research report, The Global 3D cell culture Market is segmented By Product (Scaffold-Based 3D cell culture, Scaffold-Free 3D cell culture, Microfluidics, and 3D Bioreactors), By Application (Drug Discovery, Tissue Engineering, Cancer Treatment, Regenerative medicine, Clinical, and Other Applications), By End User (Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies and Academic Institutes) & By Region- Forecast and Analysis 2021-2027. by SkyQuest

As a result of the domains technological nascence, no company currently wields significant influence, and the race to dominance has already begun, with companies investing in multiple 3D Cell Culture projects, acquiring a few on their way to the finish line in the domain. The top players in this market include 3D Biotek LLC (US), Advanced Biomatrix Inc. (US), Avantor Inc. (US), Becton, Dickinson, and Company (US), Corning Incorporated (US), Lonza Group (Switzerland), InSphero AG (Switzerland), Merck & Co., Inc (US), Synthecon Inc. (US), Thermo Fisher Scientific Inc. (US).

The report published by SkyQuest Technology Consulting provides in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions.

Speak with our analyst for more information:

https://skyquestt.com/speak-with-analyst/3d-cell-culture-market

SkyQuest has segmented the Global 3D Cell Culture Market based on Product, Application, End-User, and Region: 3D Cell Culture Product Outlook (Revenue, USD Million, 2021 2027)o Scaffold-Based 3D cell cultureo Scaffold-Free 3D cell cultureo Microfluidicso 3D Bioreactors 3D Cell Culture Application Outlook (Revenue, USD Million, 2021 2027)o Drug Discoveryo Tissue Engineeringo Cancer Treatmento Regenerative medicineo Clinical, and Other Applications 3D Cell Culture End-User Outlook (Revenue, USD Million, 2021 2027)o Research Laboratories and Instituteso Biotechnology and Pharmaceutical Companieso Academic Institutes 3D Cell Culture Regional Outlook (Revenue, USD Million, 2021 2027)o North America U.S. Canadao Europe Germany France UK Italy Spain Rest of Europeo Asia Pacific China India Japan Rest of Asia Pacifico Central & South America Brazil Rest of CSAo Middle East & Africa GCC Countries South Africa Rest of MEA

List of Key Players of the 3D Cell Culture Market 3D Biotek LLC (US) Advanced Biomatrix Inc. (US) Avantor Inc. (US) Becton, Dickinson, and Company (US) Corning Incorporated (US) Lonza Group (Switzerland) InSphero AG (Switzerland) Merck & Co., Inc (US) Synthecon Inc. (US) Thermo Fisher Scientific Inc. (US)

About Us:

SkyQuest Technologyis leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email:[emailprotected]

Find Insightful Blogs/Case Studies on Our Website:

Market Research Case Studies

Read the original post:
The 3D Cell Culture Market is expected to reach a value of USD 3721.86 Million by 2027, at a CAGR of 13.4% (2021 2027) - Digital Journal

Flow cytometry is a well-known method for identifying cells in solution, and it is most commonly used to examine peripheral blood, bone marrow, and other body fluids. Flow cytometry is used to identify and quantify immune cells, as well as to characterize haematological tumours. Increasing global incidence and prevalence of HIV/AIDS and cancer, increasing adoption of flow cytometry techniques in research and academia, expanding public-private initiatives in the fields of immunology and immuno-oncology research, technological advancements, and the increasing incorporation of AI platforms in flow cytometry workflows, and advancements in flow cytometry software are driving the flow cytometry markets growth. Flow cytometry has emerged as a critical tool for drug discovery and development safety and exploratory purposes. This tool is used throughout the research process, from pre-clinical trials to target identification and screening.

know more https://skyquestt.com/report/flow-cytometry-market

Flow cytometry can analyze a large number of particles in a short amount of time and provide statistically reliable information about cell populations. These capabilities, combined with its multi-parametric approach, make flow cytometry more suitable for use in drug discovery and development processes in the pharmaceutical and biopharmaceutical industries. Furthermore, biomarker research has become an essential component of drug discovery and development. It provides valuable evidence to guide clinical decisions, evaluates drug pharmacodynamics, and assists with drug filings with regulatory bodies. This also boosts a drugs market value and accelerates the development process. Flow cytometry is widely used in biomarker research to monitor cell population development and differentiation, assess target engagement and biomarker expression in cells, and evaluate cell functions and signaling events. Furthermore, biomarker research has become an essential component of drug discovery and development. It provides valuable evidence to guide clinical decisions, evaluates drug pharmacodynamics, and assists with drug filings with regulatory bodies.

Read market research report, Global Flow Cytometry Market Segmented By Product (Instruments (Cell Analyzers, Cell Sorters), Reagents & Consumables, Software, Accessories, Services) By Technology (Cell-based, Bead-based) By Application (Research (Pharmaceutical (Drug Discovery, Stem Cell, In Vitro Toxicity), Apoptosis, Cell Sorting, Cell Cycle Analysis, Immunology, Cell Viability), Industrial, Clinical (Cancer, Organ Transplantation, Immunodeficiency, Hematology), By End-use (Commercial Organizations, Hospitals, Academic Institutes, Clinical Testing Labs) & By Region Forecast And Analysis 2021-2027 by SkyQuest

Get sample report https://skyquestt.com/sample-request/flow-cytometry-market

Developing a novel effective reagent is a complex process that includes a variety of challenges such as variations in fluorochrome brightness and marker expression levels, issues with the stability of some fluorochromes, and optical background issues (due to significant emission spill over from non-primary fluorescent reagents) (Source: Becton, Dickinson, and Company White Paper). Provided this, it is reasonable to conclude that one of the major challenges that manufacturers face in the flow cytometry reagents market is the development of reagents (that have multicolour capabilities and provide high speed, sensitivity, and ease of use in flow cytometry processes).Maintenance costs and a variety of other indirect expenses increase the total cost of ownership of these instruments. As a result, high product installation costs and other related expenses impede optimal adoption of flow cytometry instruments in clinical and research applications, particularly in developing countries. Moreover, flow cytometry instruments are equipped with advanced features and functionalities, making them expensive. Countries such as China, Japan, India, and South Korea provide significant growth opportunities for major players in the global flow cytometry market. These opportunities for growth can be attributed to increased research initiatives across key countries, low regulatory barriers, continuous improvements in healthcare infrastructures, a growing patient population, rising healthcare expenditures, and the strengthening distribution networks of market leaders in these regions. To leverage on the growth opportunities in these countries, players in the flow cytometry market are increasingly focused on expanding their regional product offerings and enhancing their presence in emerging markets through various growth strategies such as expansions, partnerships, and collaborations, among others.

The prominent players in the flow cytometry market are Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., and Luminex Corporation. These companies have adopted both organic and inorganic growth strategies, such as product launches and acquisitions, to maintain their leading positions in the flow cytometry market.The report published by SkyQuest Technology Consulting provides in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions.

Speak to analyst https://skyquestt.com/speak-with-analyst/flow-cytometry-market

SkyQuest has segmented the Global Flow Cytometry Market based on Product, Technology, Application, End-Use and Region: Flow Cytometry Market By Product (Revenue, USD Million, 2021 2027)o Instruments Cell Analyzers Cell Sorterso Reagents & Consumableso Softwareo Accessorieso Services Flow Cytometry Market By Technology (Revenue, USD Million, 2021 2027)o Cell-basedo Bead-based Flow Cytometry Market By Application (Revenue, USD Million, 2021 2027)o Research Pharmaceutical Drug Discovery Stem Cell In Vitro Toxicity Apoptosis Cell Sorting Cell Cycle Analysis Immunology Cell Viabilityo Industrialo Clinical Cancer Organ Transplantation Immunodeficiency Hematology Flow Cytometry Market By End-use (Revenue, USD Million, 2021 2027)o Commercial Organizationso Hospitalso Academic Instituteso Clinical Testing Labs Flow Cytometry Market Regional Outlook (Revenue, USD Million, 2021 2027)o North America U.S. Canadao Europe Germany France UK Italy Spain Rest of Europeo Asia Pacific China India Japan Rest of Asia Pacifico Central & South America Brazil Rest of CSAo Middle East & Africa GCC Countries South Africa Rest of MEA

List of Key Players of Flow Cytometry Market

Becton, Dickinson and Company (US) Danaher Corporation (US) Thermo Fisher Scientific, Inc. (US) Luminex Corporation (US) Agilent Technologies, Inc. (US) Sony Group Corporation (Japan) Bio-Rad Laboratories, Inc. (US) Miltenyi Biotec GmbH (Germany) Enzo Biochem, Inc. (US) Sysmex Corporation (Japan) bioMrieux S.A. (France) Cytonome/ ST, LLC (US) Sartorius AG (Germany) Cytek Biosciences, Inc. (US) Union Biometrica, Inc. (US)About Us-

SkyQuest Technology Group is a Global Market Intelligence, Innovation Management & Commercialization organization that connects innovation to new markets, networks & collaborators for achieving Sustainable Development Goals.

Contact Us-

SkyQuest Technology Consulting Pvt. Ltd.1 Apache Way,Westford,Massachusetts 01886USA (+1) 617-230-0741Email- [emailprotected]

Find Insightful Blogs :

https://skyquestt.com/insights

Continue reading here:
Flow Cytometry Market is expected to reach a value of USD 11467.80 Million by 2027, at a CAGR of 8.88% over the forecast period (2021 2027) - Digital...

This Stem Cells Market analysis sheds light on novel methodologies used by major key players in the market. It further focuses on competitive landscape, which covers all the business-related details, company description, sales growth and revenue generation rate. Industry sectors and growth size is also discussed in this market research analysis. This Stem Cells Market study report allows key participants to go through comprehensive insights into the market developments and novel product launches. Industry owners are able to make right investment in the product or service launch

Registering a CAGR of 13.02% over the forecast period, the market value of Stem Cells is expected to reach US$ 28.2 billion in the year 2027.

Main companies in the global Stem Cells market: CCBC, Vcanbio, Boyalife, Beikebiotech, Thermo Fisher Scientific (Massachusetts, U.S), Merck KGaA, Cynata Therapeutics (Victoria, Australia), AMSBIO (Abingdon, United Kingdom)

and others.

(SPECIAL OFFER: UP TO 25% DISCOUNT FOR A LIMITED TIME)

Get a sample free copy of this report:

https://www.industrydataanalytics.com/reports/stem-cells-market/inquiry?source=IDA&mode=47

This report segments the global Stem Cells market on the basis of the following types:

Umbilical Cord Blood Stem Cell

Embryonic Stem Cell

Adult Stem Cell

Others

On the basis of application, the global Stem Cells market is segmented into:

Diseases Therapy

Healthcare

Others

For a complete understanding of the market dynamics, the global Stem Cells market is analyzed into key geographies namely: United States, China, Europe, Japan, Southeast Asia, India, and others. Each of these regions is analyzed on the basis of market findings in major countries in these regions for a macro-level understanding of the market.

Some of the Key Questions Answered in the Stem Cells Market Report:-Short-Term & Long-Term factors that will affect the Industry due to COVID-19. What is the Market Growth, Sales for each Region/Country, Production, Consumption, Import-Export, Trends, Latest Development, etc.?

-Historical, Present and Future market development, growth and market size till the forecast period.

-What are the key regions or segments that will drive the market in the near future?

-Comprehensive mapping of the key participants and the latest strategies adopted by the players in the Industry. Manufacturers behavior analysis.

Detailed Qualitative analysis and Quantitative insights presented in the report that is helpful for future growth.

The research includes historic data from 2015 to 2020 and forecasts until 2027 which makes the reports an invaluable resource for industry executives, marketing, sales, and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Get full report description with TOC:

https://www.industrydataanalytics.com/reports/stem-cells-market?source=IDA&mode=47

* If you need anything more than these, let us know and we will prepare the report according to your needs.

INDUSTRY DATA ANALYTICS About

IndustryDataAnalytics is your single point market research source for all industries including pharmaceutical, chemicals and materials, energy resources, automobile, IT, technology and media, food and beverages, and consumer goods, among others

Contact Us:

Head of Sales: Mr. Irfan Tamboli +1 (704) 266-3234 |

contact@industrydataanalytics.com

Link:
Stem Cells Market Competitive Insights And Global Outlook 2022 To 2027 Vcanbio, Boyalife, Beikebiotech, Thermo Fisher Scientific (Massachusetts, US),...

Over the course of the 2021-22 academic year, seven faculty members across the UMass Amherst campus have been named the recipients of National Science Foundation (NSF) CAREER awards.

The Faculty Early Career Development (CAREER) Program is a foundation-wide activity that offers the National Science Foundation's most prestigious awards in support of early-career faculty who have the potential to serve as academic role models in research and education and to lead advances in the mission of their department or organization.

Manning College of Information and Computer Sciences

Manning College of Information and Computer Sciences (CICS) professors Jie Xiong and Hamed Zamani have been awarded CAREER grants from the National Science Foundation for their work on long-range wireless sensing and the development of search engines that work on a conversational model, respectively. This brings the cumulative number of CAREER awards for CICS to 34.

Xiong, whose award totaled $621,984 is focusing on the improvement of a ubiquitous technology in daily lifesensors, which are embedded in a diverse range of systems such as smartphones, wearables, gaming devices, medical equipment and automobiles. Wireless sensing, an emerging alternative to conventional sensors, uses wireless signals to sense human beings and the surrounding environment using contact-free and sensor-free methods, which can be especially beneficial for pandemic and disaster response. The technology also promises to benefit a large spectrum of disciplines including elderly care, human-computer interaction and environment monitoring.

Xiong's project aims to develop fundamental theories to help people understand the underlying mechanism of long-range wireless sensing, and to apply those theories to overcome the limitations of the field, moving wide-area wireless sensing close to widespread adoption.

I am aiming to revolutionize wireless sensing and enable many new sensing applications, explains Xiong. These applications could range from soil moisture sensing for water conservation to the detection of disaster survivorseven if they are in a comathrough long-range, through-wall respiration sensing."

Zamani, who is an expert in information retrieval, search engines and machine learning, was awarded $570,863 to develop a next-generation, conversational search engine. While current search engines work on a query-response paradigm, where, for example you search best pizza in Amherst, Massachusetts and then wade through more than six-million results, a conversational search engine might ask a series of clarifying questions to arrive at a curated selection of results.

In particular, Zamani will work on developing new theories and models that can help advance the field of conversational information retrieval.

College of Natural Sciences

The College of Natural Science (CNS) has been awarded three CAREER grants during this cycle, bringing the total number to 60.

Owen Gwilliam, in the Department of Mathematics and Statistics, has been awarded $546,061 for his research into various theories of higher algebra that occupy a point of intersection between math and physics. In particular, higher algebra has enlarged quantum field theory, which plays an active role in everything from particle theory to condensed matter physics.

Recently, the exchange between physics and math has yielded a new tool, called factorization algebras.

Mathematics and physics have engaged in a long dialogue for centuries, says Gwilliam, starting with Newton's invention of calculus and its applications to gravity. The rise of quantum field theory in the twentieth century has added a new topic for avid conversation. My research involves exploring how recent mathematical innovations from higher algebra clarify aspects of quantum field theory, with a special focus on the Kapustin-Witten theories (from physics) and their connection to the geometric Langlands program (in math).

However, one difficulty in pursuing interdisciplinary is communicating across disciplinary boundaries. A key component of Gwilliams project is to create chances for researchers at all levels to become fluent in speaking to both disciplines and, moreover, to build direct personal bridges. At the graduate and postdoctoral level, the project will run annual summer schools for both mathematicians and theoretical physicists, focused on topics of mutual interest. In addition, each academic year, it will produce high-quality, online masterclasses by experts about such topics, with lecture notes and exercises. Finally, the project will support summer research for undergraduates, tackling problems between mathematics and physics, from the University of Massachusetts and nearby Five Colleges.

Soil scientist Marco Keiluweit, of the Stockbridge School of Agriculture, has been awarded $468,283 to better understand how the complex science of how soils store carbon. Soils store more than twice as much carbon as the atmosphere and biosphere combined, and more than 90% of this soil carbon is stored in organic compounds intimately associated with reactive minerals. Such mineral-organic associations (MOAs) can protect carbon compounds against microbial or enzymatic attack for centuries to millennia. However, plant roots and associated microbes in the rhizosphere have a well-known ability to transform minerals through dissolution and exchange reactions. Yet, the effect that roots and microbes have on the MOAs remains poorly understood.

Keiluweits overall objective is to develop a mechanistic understanding of the dynamics and vulnerability of MOAs in the rhizosphere and to train diverse, creative and technically skilled environmental scientists. Keiluweits team will launch a collaboration with Holyoke Community College to increase representation of low-income and minority students in UMass's environmental science degree program and create a new course incorporating Design Thinking approaches in order to provide graduate students and postdocs with the creative problem-solving and collaborative skills urgently needed to solve the complex environmental challenges facing society today.

Lillian Fritz-Laylin, an evolutionary cell biologist, has been awarded $1,050,000 to investigate a fungus, known as B. dendrobatidis, that is decimating hundreds of amphibian species around the world. It seems that the fungus interacts with the mucus membrane that coats many amphibians, but how, exactly, is unknown.

The ultimate goal of this project, says Fritz-Laylin, is to determine how B. dendrobatidis responds to exposure to molecules found in amphibian mucus. Establishing the molecular mechanism by which mucus induces changes in B. dendrobatidis may be used to develop remediation strategies to reverse the decline in amphibians caused by B. dendrobatidis infection.

Part of Fritz-Laylins work will involve creating a hands-on laboratory course will be developed for approximately 24 students per year for the duration of the project. These students will gain practical experience in designing, executing and interpreting the results of their own experiments, preparing them to participate in the STEM workforce. The development, evaluation and dissemination of a modular laboratory course framework will allow additional University of Massachusetts Amherst faculty, as well as extra-mural faculty, to develop new courses and/or quickly revise existing courses to improve scientific reasoning in undergraduate students. Finally, the adaptation of these materials into a workshop for middle school girls will broaden participation in STEM fields.

College of Engineering

Chemical engineering assistant professors Peng Bai and Ashish Kulkarni have each been awarded prestigious five-year grants through the National Science Foundation Early Career Development (CAREER) Program. Bai and Kulkarni's CAREER awards are for $551,035 and $637,359, respectively.

Kulkarnis research combines nanotechnology, engineering and immunobiology to create nanoscale technologies that stimulate the immune system in specific ways to treat diseases and improve human health. He will use the CAREER grant to focus his research on the relationship between nanomaterials and inflammasome activation.

One of the biggest questions in the field of immunoengineering today is how do these nanomaterials interact with immune cells, and what kind of interactions do they create, whether positive or unwanted? Kulkarni says. This project is about understanding and mapping these interactions to develop guidelines for future generations of nanomaterials that are more effective and beneficial.

The proposed study will enhance our fundamental understanding of nanomaterial-immune cell interactions and enable us to develop novel approaches that can effectively target inflammasomes to treat chronic diseases, substantially contributing to improving human health and quality of life, Kulkarni says.

Bais research focuses on developing molecular simulation and first-principles methods to study separation, energy conversion and storage in complex materials systems.

Millions of tons of alcohols and carboxylic acids, used to create polymers, food additives, solvents, and pharmaceuticals, are produced industrially via catalytic carbonylation every year, Bai says. Because this process makes use of expensive rare-metal catalysts and requires corrosive chemical agents to promote the desired reactions, the result is stringent and costly reactor designs, complex catalyst recycling schemes, and environmentally unfriendly waste streams.

With the CAREER grant, Bai will develop computer models to discover effective porous solid-acid catalysts as a technologically and environmentally appealing alternative.

Faculty in the College of Engineering have been awarded 38 NSF CAREER awards since the award's inception in 1995. With Bai and Kulkarni's awards, all five current chemical engineering assistant professors in the College of Engineering have now received an NSF CAREER award.

Read this article:
Seven UMass Amherst Faculty Members Receive NSF CAREER Awards in 2021-22 Academic Year - UMass News and Media Relations

Netta Blondheim-Shraga, PhD Appointed as VP R&DAntal Pearl-Lendner, Adv. Appointed as Chief Legal Counsel

NEW YORK, May 12, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced two senior management appointments. Netta Blondheim Shraga, PhD has been appointed as VP, Research & Development, and Antal Pearl-Lendner, Adv. has been appointed to the newly created position of Chief Legal Counsel. Both will report directly to Chaim Lebovits, CEO.

"We are thrilled to welcome Netta and Antal, each of whom brings valuable experience in their respective areas of R&D and Legal Affairs," said Chaim Lebovits, Chief Executive Officer of BrainStorm. "As we prepare the company for growth, it is important that we continue to build out our senior executive team and attract professionals with the appropriate skillsets. We look forward to leveraging their backgrounds as we execute on our mission to bring autologous cell therapies to patients with debilitating neurodegenerative diseases."

Dr. Blondheim-Shraga will be responsible for advancing the company's pipeline and steering the R&D team towards significant breakthroughs in the field of cell therapy and development of novel solutions to positively impact patients' health. Dr. Blondheim-Shraga joins BrainStorm with over 14 years of translational research experience in academic, biotech and pharma settings, having led teams in Israel, USA and China, combining scientific, entrepreneurial and management skills. Prior to joining BrainStorm, she was Project Leader on the Academic Affairs team at Teva Pharmaceuticals, Israel. In this role, she managed a portfolio of diverse and highly impactful strategic scientific collaborations with Teva's academic partners and managed Teva's involvement in several international consortia. Prior to Teva, she was Study Director and Senior Scientist at CrownBio, San Diego, CA. Earlier in her career, she was a Senior Scientist at Lifemap Sciences LTD in Tel-Aviv and served as Scientific Advisor to ImmunoHiTech LTD, Ramat Hasharon, Israel for several years. Dr. Blondheim-Shraga received a PhD from the Faculty of Medicine, Bar-Ilan University, Safed, Israel, an MSc Med from The Faculty of Medicine, Tel Aviv University, Israel and a BSc Med from The Faculty of Medicine, Hebrew University Jerusalem, Israel.

Antal Pearl-Lendner, Adv. is an experienced bilingual attorney with a proven track record in legal and business development capacities. Prior to joining Brainstorm, Ms. Pearl-Lendner spent 8 years at Mizrahi-Tefahot Bank in Israel where her responsibilities included spearheading bank-wide complex projects, negotiating large scale international contracts and providing ongoing advice regarding the international activities of the bank. Before her tenure at the bank, she worked at GE Capital in Chicago and Connecticut, USA, where she served in GE's premier commercial leadership program, working in business development, strategy & analytics. Earlier in her career, Ms. Pearl-Lendner was an Associate Attorney in the international department of Caspi & Co. Advocates & Notaries in Tel Aviv, Israel. In this role she represented clients in M&A transactions and led due diligence processes for investments ranging from $5M to $350M. Ms. Pearl-Lendner received an MBA from the MIT Sloan School of Management in Cambridge, Massachusetts and an LLB from Tel Aviv University.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect," "likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our products and services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation; the impacts of the COVID-19 pandemic on our clinical trials, supply chain, and operations; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

CONTACTS

Investor Relations:John MullalyLifeSci Advisors, LLCPhone: +1 617-429-3548 [emailprotected]

Media:Uri Yablonka[emailprotected]

View original content:https://www.prnewswire.com/news-releases/brainstorm-strengthens-executive-team-with-key-appointments-in-rd-and-legal-301546060.html

SOURCE BrainStorm Cell Therapeutics Inc.

See the original post here:
BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal - GuruFocus.com

Asymmetrex reports algorithms for rapid quantification of therapeutic stem cells

BOSTON (PRWEB) June 09, 2022

In 2021, stem cell biotechnology company Asymmetrex announced its award of a Technical Project grant from ARMI|BioFabUSA. ARMI assembles, integrates, and leads academic, government, and industry partners in coordinated research and development with a unique vision of accelerating innovation in the biomanufacturing of products and treatments for regenerative medicine. Asymmetric became a member company of ARMI|BioFabUSA less than a year before being selected to evaluate whether its unique tissue stem cell counting technology could be successfully adapted for use in cell and tissue biomanufacturing.

Now, a little over a year later, the company is reporting the results of its evaluation in two presentations in ARMI|BioFabUSAs Spring Meeting in the Millyard R&D summit, scheduled for September 7-9. On the opening morning of the summit on September 7, Asymmetrex presented an interactive Technology Demonstration of the capabilities of the newly automated software for its kinetic stem cell (KSC) counting technology. Automation is one of the four main ARMI|BioFabUSA principles for accelerating biomanufacturing capability. The others are modularity, scalability, and closed operability.

The new software automation provides a tenfold increase in the speed of determinations of changes in the relative fractions for tissue stem cells and their related cell subpopulations during biomanufacturing. No other technology has this capability; and the new software automation allows it to be performed with greater speed and even greater precision.

Asymmetrexs second presentation was a poster displayed at the summits poster session on the evening of September 8. The poster provides a first look at the industry potential of validated rapid-counting algorithms for therapeutic stem cells. The speed and precision achieved by the software automation makes the derivation of these unique biological equations routine. Called Rabbit algorithms for their speed, Asymmetrex is currently developing online calculators for access to their use. The calculators use simple conventional cell count data to determine the specific fraction or dose of the tissue stem cells present in a biomanufacturing or treatment sample.

The facility and speed of the rapid stem cell counting algorithms enable straightforward integration of KSC counting for monitoring therapeutic stem cells in cell and tissue biomanufacturing processes. Asymmetrex is now designing a pilot online rapid-counting beta-test with ARMI|BioFabUSA bioengineers who collaborated in the research. Asymmetrex founder, James L. Sherley, M.D., Ph.D., expresses the companys excitement with the new advances, Determining the dose of therapeutic stem cells is now more than just possible for the first time. With ARMIs support it's getting easy to do, too!

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The companys U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems stem cell-specific quantification and stem cell expansion that have stood in the way of more-effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets kinetic stem cell (KSC) counting, the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation medicine and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute | BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio).

Share article on social media or email:

The rest is here:
Asymmetrex Presents New Developments in its Rapid Stem Cell Counting Technology at the ARMI|BioFabUSA Meeting in the Millyard on Regenerative Medicine...

Novel agents seek to improve and expand the efficacy of the current standard of care for patients with acute graft-vs-host disease, specifically those with high-risk disease.

High-dose systemic steroid administration has limited durability for patients who develop acute graft-vs-host disease (aGVHD). Novel agents seek to improve and expand the efficacy of the current standard of care for patients, specifically those with high-risk disease.

We all want to find new agents that are more effective as frontline therapy for [patients with] aGVHD, said Corey S. Cutler, MD, MPH, FRCPC, in an interview with OncologyLive. Even with a very potent anti-inflammatory [such as] steroids, only 50% of our patients are getting a real benefit. Anything that we could use in the frontline setting that will help improve those response rates certainly seems like it will be a very welcome addition to our armamentarium.

A complication of allogeneic hematopoietic stem cell transplant, aGVHD occurs in approximately 50% of patients who undergo this procedure. Onset of aGVHD usually occurs within 100 days of transplant and involves the skin, liver, and gastrointestinal (GI) tracts. Initiation of high-dose corticosteroids is the current standard of care; however, nearly half of patients become refractory to treatment.1

Efficacy data for high-dose corticosteroids alone have demonstrated inferior response rates among individuals with high-risk aGVHD vs those with standard aGVHD. For example, a retrospective analysis stratified patients by risk status and reported that the overall response rate at day 28 after treatment was 44% (95% CI, 38%-50%) among 269 patients with high-risk aGVHD vs 68% (95% CI, 66%-70%) among 1454 patients with standard-risk aGVHD.2 The complete response rates (CR) were 27% (95% CI, 22%-33%) and 48% (95% CI, 45%-51%), respectively with partial response (PR) of 16% (95% CI, 12%-21%) and 21% (95% CI, 19%-23%).2

To address this unmet need, investigators have initiated the phase 3 pivotal EQUATOR trial (NCT05263999), which will evaluate the novel monoclonal antibody, itolizumab (Alzumab), in combination with standard-of-care corticosteroids vs placebo in patients with aGVHD.3

We know that CD6 is a costimulatory receptor found on activated CD4 and CD8 T cells. We also know that the ligand called ALCAM, is expressed on antigen-presenting cells, as well as the inflamed tissues in the skin and GI tract. Since those [receptors] are [present in] the target organs of aGVHD, preventing these T cells from getting to their target makes a lot of sense [and] itolizumab is a promising compound, said Cutler, who is medical director of the Adult Stem Cell Transplantation Program, director of clinical research, stem cell transplantation, and director of the Stem Cell Transplantation Survivorship Program at Dana-Farber Cancer Institute in Boston, Massachusetts.

Itolizumab, a first-in-class anti-CD6 monoclonal antibody targets the CD6activated leukocyte cell adhesion molecule (ALCAM) pathway, which modulates the activity of T cells that drive immunoinflammatory diseases, and has demonstrated early activity as a first-line therapy for patients with high-risk aGVHD in the phase 1/2 EQUATE trial (NCT03763318).4,5

Itolizumab is a monoclonal antibody that binds to the CD6 [protein], which is expressed on immune effector, or proinflammatory T cells; it is part of the costimulation pathway, John Koreth, MBBS, DPhil, said in an interview with OncologyLive. Interestingly, [itolizumab] is slightly different [from other agents] in that it does not delete or kill the cells that it binds to, but results [in the] shedding of CD6 from the surface of the cells, and switches [these cells] from a CD6-high to a -low state. By doing so, it appears to switch them from a proinflammatory immune effector cell to a less inflammatory, regulatory T-cell phenotype. That is part of the mechanism [of action of the agent,] and interfering with the CD6 costimulation is another way of blunting the inappropriate immune activity that we believe is part of the underlying pathology in GVHD, explained Koreth, who is the director of Translation Research and Stem Cell Transplantation and professor of medicine at Harvard Medical School.

The EQUATE trial comprised 2 parts: a 3 + 3 dose-escalation portion and a randomized double-blind phase.6 The phase 1b/2 trial tested 3 dose levels0.4, 0.8, and 1.6 mg/kg, Cutler said. According to our pharmacokinetic and pharmacodynamic studies, the 0.4-mg/kg dose was probably insufficient, but there was really no advantage of the 1.6-mg/kg dose [compared with] 0.8 mg/kg.

At the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation, investigators reported updated data from the EQUATE study. At day 15 of treatment, the complete response rate was 52% among the 20 patients who received itolizumab and was maintained through day 29. The overall response rate was also assessed at days 15 and 29 and was reported at 74% and 65%, respectively. At day 29, 72% of patients were still receiving treatment with corticosteroids.5

End of treatment was considered day 57, at which time 50% of patients had durable response. In a follow-up analysis, 45% of patients had an ongoing response at day 169 and the nonrelapse mortality rate was 35% with an estimated overall survival rate of 65%.5

An observational end point of the EQUATE study was the reduction of corticosteroid use, which investigators reported that patients either maintained steroid reduction from day 29 and/or continued tapering through day 169. These are the patients who we are concerned would not be likely to achieve a good response to the standard of care, which is corticosteroids alone, Koreth said. No FDA-approved therapies [are available] for this indication, but we do have patients who are routinely treated with steroids across the world.

In terms of safety, at the interim analysis investigators reported that all participants experienced at least 1 adverse effect (AE), with serious AEs reported among 65% of patients. A concern for this patient population is infection, which was reported among 43% of participants.5 I want to underscore that this is a sick population; these are patients with acute involvement, typically of the lower intestinal tract, Koreth said noting that individuals often present with ulceration of the intestinal epithelium, risk of bleeding, and diarrhea.

We expect high rates of severe adverse effects [AEs] based on the nature of this illness. [That being said, we] did see infections [with the agent, although] the rates were not dramatically different than what we would have expected. Although there were rates of significant AEs, including a significant rate of infections, that did not differ from what we would have expected a priori going into the study, given the illness of these patients, Koreth said.

Building on the data from EQUATE, Koreth highlighted the data used to inform the protocol for the phase 3 design. When [investigators] looked the specific subset of patients who were treated within 3 days of the onset of steroids, which is the trial design for the [phase 3] study, the CR rate was [61%] and the ORR was [67%]again, this is across all dose levels, Koreth said. [These findings] did suggest a response rate that was substantial. [It is important to remember, however, that this] was an uncontrolled analysis, which is why the follow-up [phase 3] study is so critical.

EQUATOR will enroll approximately 200 patients with grade 3/4 aGVHD, or grade 2 aGVHD with lower GI involvement, a population of patients at a higher risk to develop steroid refractory disease, Cutler said. The randomized trial is an extension of the phase 1b/2 study [and] is the proof phase [in which] that we will [use] the preliminary data that weve gathered [to meet] the main objective [of the study]: to determine whether the addition of itolizumab to corticosteroids is in fact better than steroids alone for the initial therapy of aGVHD, Cutler said.

EQUATOR will enroll approximately 200 patients with grade 3/4 aGVHD, or grade 2 aGVHD with lower GI involvement, a population of patients at a higher risk to develop steroid refractory disease, Cutler said. Staging will be determined using the Mount Sinai Acute GVHD International Consortium (MAGIC) grading criteria.3 Grade 3 disease is defined as stage II/III liver and/or stage II/III lower GI involvement with stage 0-III skin and/or stage 0/I upper GI involvement. Grade 4 disease is defined as stage IV skin, liver, or lower GI involvement with stage 0/I upper GI involvement.7 Additionally, patients must be 12 years or older and have undergone initial allogenic hematopoietic stem cell transplant, have evidenced of myeloid engraftment.3

Patients will be randomly assigned to receive itolizumab within 3 days of the first administration of high-dose corticosteroids or placebo. Based on the data from EQUATE, itolizumab administered at 0.8 mg/kg once every 2 weeks for 6 doses will be used in EQUATOR following an initial dose of 1.6 mg/kg.3 Steroid tapering is recommended.

Were [evaluating] to itolizumab in the frontline setting for [patients with] aGVHD [in an attempt to] both increase the response rate to initial therapy with corticosteroids, as well as prevent patients from having early relapses when we start tapering their corticosteroids, Cutler said. Steroids are very toxic in the acute setting and anything we can do to minimize our patients exposure to this class of drugs will be beneficial in the long term, as long as response rates are not compromised by giving lower doses of steroids.

The primary end point is early disease response evaluated at 29 days after initiation of treatment. The secondary objectives include durability of response, corticosteroid use, survival outcomes, and chronic GVHD incidence.

[Itolizumab] could be a potential game changer, Koreth said. If patients have a therapy that can rapidly induce a CR that is durable, allows us to taper steroids, and improves survival, then that would be the new standard of care for these patients, who, at this point, have a very significant unmet medical need. [This] is a rigorous trial design, and I hope, if successful, there will be a straight path to approval of the medication so that patients in need can receive it.

Go here to see the original:
Investigators Seek to Push Combination Therapy to the Front-line Treatment of aGVHD - OncLive

Stem Cells Market: A thorough analysis of statistics about the current as well as emerging trends offers clarity regarding the Stem Cells Market dynamics. The report includes Porters Five Forces to analyze the prominence of various features such as the understanding of both the suppliers and customers, risks posed by various agents, the strength of competition, and promising emerging businesspersons to understand a valuable resource. Also, the report spans the Stem Cells research data of various companies, benefits, gross margin, strategic decisions of the worldwide market, and more through tables, charts, and infographics.

To Understand Business Strategies, Request For a Sample Report at:https://www.industrydataanalytics.com/reports/stem-cells-market/inquiry?Mode=A130

Key players in the global Stem Cells market covered in are:

CCBC, Vcanbio, Boyalife, Beikebiotech, Thermo Fisher Scientific (Massachusetts, U.S), Merck KGaA, Cynata Therapeutics (Victoria, Australia), AMSBIO (Abingdon, United Kingdom)

Market Segmentation

Segmentation by type:

Umbilical Cord Blood Stem Cell

Embryonic Stem Cell

Adult Stem Cell

Others

Segmentation by application:

Diseases Therapy

Healthcare

Others

The study will assist both existing and new aspirants in the Stem Cells market in establishing and investigating the industrys needs, market size, and competition, based on data collected from multiple research methodologies as well as trustworthy data sources. Reports provide graphical estimates for the coming years based on recent events and historical data. Researchers employed top-down and bottom-up approaches to collect data and estimate income for all regions of the Stem Cells market.

Regional Analysis for Stem Cells Market:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia-Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

The objective of the study is to define the Stem Cells market sizes of different segments and countries in previous years and to forecast the values for the next five years. The report is designed to incorporate both qualified qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about crucial aspects such as drivers and restraining factors that will define the future growth of the Stem Cells market.

Detailed TOC of Global Stem Cells Market @https://www.industrydataanalytics.com/reports/stem-cells-market?Mode=A130

Reasons to buy

Table of Contents:

Customization of the Report:

IndustryDataAnalytics provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

IndustryDataAnalytics is your single point market research source for all industries including pharmaceutical, chemicals and materials, energy resources, automobile, IT, technology and media, food and beverages, and consumer goods, among others.

Head of Sales: Mr. Hon Irfan Tamboli

+1 (704) 266-3234 | contact@industrydataanalytics.com

Here is the original post:
Stem Cells Market 2022 Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2027 The Greater Binghamton Business Journal - The...